|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||493.60 - 515.00|
|52 Week Range||312.00 - 564.75|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||169.11|
|Forward Dividend & Yield||6.75 (1.34%)|
|Ex-Dividend Date||Aug 19, 2020|
|1y Target Est||567.59|
The Indian pharma stock surge dates to April, when the ban on exporting hydroxycholoroquine was lifted. The sector's stocks jumped, but the gains won't last as U.S. scrutiny returns.
India's Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world's third worst-hit nation. Favipiravir, along with another antiviral, remdesivir, has emerged as one of the most sought-after drugs at hospitals fighting COVID-19 in India, which saw a surge of 50,000-plus infections for the sixth straight day on Tuesday. Sun's version of favipiravir, to be called FluGuard, will cost 35 rupees (47 cents) per 200 mg tablet, making it the cheapest version available.
Indian drugmaker Sun Pharmaceutical Industries Ltd said on Friday it was testing a plant-derived drug, AQCH, for the potential treatment of COVID-19 as part of a mid-stage trial, with results expected by October. AQCH is derived from tropical, climbing shrub cocculus hirsutus, which is used in Asia for its apparent medicinal properties. The company said the trial will be conducted across 12 centers in India in 210 patients and a human safety study of the drug has been completed.